华润双鹤药业股份有限公司2021年限制性股票激励计划回购注销实施公告详解

要点概述

• 华润双鹤药业股份有限公司（以下简称“公司”）公告，将对2021年限制性股票激励计划中不再符合激励条件的3名激励对象已获授但尚未解除限售的174,998股限制性股票进行回购注销。
• 注销股份的日期为2026年3月16日，注销后公司总股本将由1,038,757,509股减少至1,038,582,511股。
• 本次回购注销完成后，剩余股权激励限制性股票为5,604,620股。
• 公司董事会声明决策程序和信息披露符合法律法规要求，并已告知相关激励对象，未有异议。
• 北京市中伦律师事务所出具了合法合规的结论性法律意见书。

详细内容

一、回购注销的背景与原因

公司于2025年10月23日召开董事会及监事会，审议通过了《关于回购注销部分激励对象已获授但尚未解除限售的限制性股票的议案》。公告披露，3名激励对象中，1名因退休，2名因组织调动，不再符合激励条件。根据《2021年限制性股票激励计划（2022年12月修订稿）》及2022年第一次临时股东大会授权，公司决定回购注销其已获授但尚未解除限售的174,998股限制性股票。

二、回购注销程序与结果

公司已于2025年12月26日履行了通知债权人程序，在约定申报时间内无债权人提出异议。公司在中国证券登记结算有限责任公司上海分公司开设回购专用证券账户（账户号码：B884648689），并向其递交回购过户申请。预计该部分股份将在2026年3月16日完成注销，随后将依法办理工商变更登记手续。

三、股份结构变动

四、对股东及投资者的重要提示

• 本次回购注销导致公司总股本略微减少，影响有限，但显示公司对股权激励计划的严格执行和规范管理，有利于维护公司治理结构的规范性。
• 激励计划调整未造成现有股东权益稀释，但可能对股权激励对象和公司人力资源结构产生一定影响。
• 未有债权人提出异议，公司已承诺若因本次回购注销与激励对象产生纠纷，将自行承担相关法律责任。
• 本次事项符合法律法规及《上市公司股权激励管理办法》相关要求，确保公司回购注销程序合规。

五、法律意见及合规说明

• 北京市中伦律师事务所确认公司本次回购注销已取得必要批准与授权，方案合规，现阶段公告、专户开设和注销申请等程序已履行，公司尚需办理后续工商变更手续。

投资者需要关注的潜在影响（价敏信息）

• 此次股份回购注销，虽然数量不大，但反映公司对激励计划的严格管理，或将提升市场对公司治理的信心。
• 总股本略有减少，长期来看有助于提升每股收益（EPS），但短期影响有限。
• 如未来激励计划持续执行，或将影响公司人力资源激励结构及高管团队的稳定性，投资者可持续关注公司后续激励计划动态。

免责声明： 本文为信息整理与解读，仅供投资者参考，不构成任何投资建议。投资有风险，决策需谨慎。

English Version

China Resources Double-Crane Pharmaceutical Co., Ltd. Implementation Announcement of 2021 Restricted Stock Incentive Plan Repurchase and Cancellation

Key Highlights

• The company will repurchase and cancel 174,998 restricted shares previously granted but not yet unlocked to 3 incentive recipients who no longer meet the eligibility criteria under the 2021 restricted stock incentive plan.
• Shares will be cancelled on March 16, 2026. After cancellation, total share capital will decrease from 1,038,757,509 to 1,038,582,511 shares.
• After completion, 5,604,620 incentive shares remain in the plan.
• The Board confirms the process complies with laws and regulations, and there is no objection from the affected recipients.
• The legal review from Zhong Lun Law Firm concludes the process is legitimate and compliant.

Details

Background and Reason for Repurchase & Cancellation

On October 23, 2025, the Board and Supervisory Board approved the proposal to repurchase and cancel restricted shares for 3 recipients—1 retired, 2 transferred—who no longer meet the eligibility criteria. This follows the 2021 incentive plan (2022 revision) and the authorization of the 2022 first EGM.

Process and Results

The company completed the creditor notification process by December 26, 2025, with no objections. A special account at China Securities Depository and Clearing Corp. (Shanghai) has been opened (Account No.: B884648689) to handle the repurchase. The 174,998 shares are expected to be cancelled on March 16, 2026, after which business registration changes will be made.

Change in Share Structure

Key Points for Shareholders and Investors

• The repurchase and cancellation reduce total share capital slightly, reflecting strict management of the incentive plan and positive governance signal.
• No dilution of existing shareholder interests; no creditor objections.
• Future incentive plan adjustments may affect management structure and talent retention; investors should monitor further updates.

Legal Compliance

• Zhong Lun Law Firm confirms the repurchase process is compliant and all necessary approvals were obtained.

Potential Impact for Investors (Price Sensitive Information)

• Although the number of shares involved is small, the strict implementation of the incentive plan may positively impact market confidence in company governance.
• Total share capital reduction may slightly enhance EPS in the long term, but short-term impact is minimal.
• Ongoing incentive plan management could influence senior management stability and human resources incentives.

Disclaimer: This article is for information and interpretation purposes only and does not constitute investment advice. Please make your own investment decisions prudently.

View 华润双鹤 Historical chart here